A comparative study of the usefulness of color vision, photostress recovery time, and visual evoked potential tests in early detection of ocular toxicity from hydroxychloroquine

2011 ◽  
Vol 31 (4) ◽  
pp. 283-289 ◽  
Author(s):  
Javad Heravian ◽  
Massoud Saghafi ◽  
Naser Shoeibi ◽  
Samira Hassanzadeh ◽  
Mohammad Taghi Shakeri ◽  
...  
Keyword(s):  
Early Detection ◽  
Comparative Study ◽  
Color Vision ◽  
Recovery Time ◽  
Visual Evoked Potential ◽  
Evoked Potential ◽  
Ocular Toxicity ◽  
Photostress Recovery Time ◽  
Visual Evoked

Application of the spatiochromatic visual evoked potential to detection of congenital and acquired color-vision deficiencies

1993 ◽  
Vol 10 (8) ◽  
pp. 1818 ◽  
Author(s):  
Michael A. Crognale ◽  
Eugene Switkes ◽  
Jeff Rabin ◽  
Marilyn E. Schneck ◽  
Gunilla Hægerström-Portnoy ◽  
...  
Keyword(s):  
Color Vision ◽  
Visual Evoked Potential ◽  
Evoked Potential ◽  
Color Vision Deficiencies ◽  
Visual Evoked

Pattern electroretinogram and visual evoked potential: A comparative study

1985 ◽  
Vol 61 (3) ◽  
pp. S24-S25
Author(s):  
M. Manca ◽  
A. Polo ◽  
M.C. Cristofori ◽  
V. Tugnoli ◽  
I. Aiello ◽  
...  
Keyword(s):  
Comparative Study ◽  
Visual Evoked Potential ◽  
Evoked Potential ◽  
Pattern Electroretinogram ◽  
Visual Evoked

scholarly journals Comparison of Visual Evoked Potential in Thalassemia Patients Receiving Iron Chelation Therapy

2021 ◽  
Vol 8 (12) ◽  
pp. 125-129
Author(s):  
Mridul Yadav ◽  
Shelja Deswal ◽  
Deswal .
Keyword(s):  
Side Effects ◽  
Iron Overload ◽  
Visual Evoked Potential ◽  
Evoked Potential ◽  
Chelation Therapy ◽  
Iron Chelation ◽  
Thalassemia Major ◽  
Iron Chelation Therapy ◽  
Ocular Toxicity ◽  
Visual Evoked

Patients of thalassemia require iron chelation therapy for the treatment of iron overload in the form of desferrioxamine (DFO), combination of DFO and deferiprone and oral deferiprone only. One of the side effects of DFO is ocular toxicity. Present study was conducted to elicit the subclinical effects of DFO on visual pathways by doing Visual Evoked Potential (VEP). Forty five patients of thalassemia major were divided into three groups (I, II &III) based on their iron chelation therapy as desferrioxamine, combination of desferrioxamine& deferiprone and only deferiprone respectively. VEP was recorded in each group and comparison was done. In VEP P100 was significantly prolonged in the group of thalassemia patients receiving DFO and combination of DFO and deferiprone suggesting vulnerability to ocular toxicity of DFO. We can suggest that in patients receiving chronic DFO therapy, VEPs may be considered to monitor the toxic effects of DFO on visual system. Keywords: Thalassemia, iron chelation, visual evoked potential.

Sign in / Sign up

Export Citation Format

Share Document